Head-To-Head Comparison: Oncomed Pharmaceuticals (OMED) vs. Its Competitors

Oncomed Pharmaceuticals (NASDAQ: OMED) is one of 184 publicly-traded companies in the “Biotechnology & Medical Research” industry, but how does it contrast to its competitors? We will compare Oncomed Pharmaceuticals to related companies based on the strength of its dividends, valuation, risk, earnings, profitability, institutional ownership and analyst recommendations.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Oncomed Pharmaceuticals and its competitors, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Oncomed Pharmaceuticals 0 6 2 0 2.25
Oncomed Pharmaceuticals Competitors 532 2374 6552 124 2.65

Oncomed Pharmaceuticals currently has a consensus target price of $6.00, indicating a potential upside of 18.81%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 17.71%. Given Oncomed Pharmaceuticals’ higher possible upside, research analysts plainly believe Oncomed Pharmaceuticals is more favorable than its competitors.

Earnings and Valuation

This table compares Oncomed Pharmaceuticals and its competitors gross revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Oncomed Pharmaceuticals $25.15 million -$103.10 million -2.67
Oncomed Pharmaceuticals Competitors $217.29 million -$39.39 million -67.75

Oncomed Pharmaceuticals’ competitors have higher revenue and earnings than Oncomed Pharmaceuticals. Oncomed Pharmaceuticals is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.


This table compares Oncomed Pharmaceuticals and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Oncomed Pharmaceuticals -298.57% N/A -48.03%
Oncomed Pharmaceuticals Competitors -3,317.60% -534.55% -39.71%

Volatility & Risk

Oncomed Pharmaceuticals has a beta of 2.8, indicating that its stock price is 180% more volatile than the S&P 500. Comparatively, Oncomed Pharmaceuticals’ competitors have a beta of 1.56, indicating that their average stock price is 56% more volatile than the S&P 500.

Institutional & Insider Ownership

39.4% of Oncomed Pharmaceuticals shares are held by institutional investors. Comparatively, 48.0% of shares of all “Biotechnology & Medical Research” companies are held by institutional investors. 32.8% of Oncomed Pharmaceuticals shares are held by insiders. Comparatively, 14.5% of shares of all “Biotechnology & Medical Research” companies are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.


Oncomed Pharmaceuticals competitors beat Oncomed Pharmaceuticals on 7 of the 12 factors compared.

Oncomed Pharmaceuticals Company Profile

OncoMed Pharmaceuticals, Inc. (OncoMed) is a clinical-stage biopharmaceutical company. The Company focuses on discovering and developing therapeutics that address the fundamental biology driving cancer’s growth, resistance, recurrence and metastasis. The Company’s therapeutic candidates and preclinical programs include Demcizumab (Anti-DLL4, OMP-21M18), Tarextumab (Anti-Notch2/3, OMP-59R5), Vantictumab (anti-Fzd7, OMP-18R5), Ipafricept (Fzd8-Fc, OMP-54F28), Brontictuzumab (Anti-Notch1, OMP-52M51), Navicixizumab (Anti-DLL4/VEGF Bispecific, OMP-305B83), Anti-RSPO3 (OMP-131R10), Anti-TIGIT (OMP-313M32) and GITRL-Fc trimer (OMP-336B11). Demcizumab is a humanized monoclonal antibody that inhibits Delta-like Ligand 4 (DLL4) in the Notch signaling pathway. Tarextumab is a human monoclonal antibody that binds to both the Notch2 and Notch3 receptors.

Receive News & Ratings for Oncomed Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncomed Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply